Principal Financial Group’s TherapeuticsMD TXMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-2,466
| Closed | -$47K | – | 2644 |
|
|
2022
Q1 | $47K | Buy |
2,466
+145
| +6% | +$2.28K | ﹤0.01% | 2488 |
|
|
2021
Q4 | $41K | Sell |
2,321
-799
| -26% | -$23.9K | ﹤0.01% | 2490 |
|
|
2021
Q3 | $116K | Buy |
3,120
+173
| +6% | +$7.68K | ﹤0.01% | 2486 |
|
|
2021
Q2 | $176K | Buy |
2,947
+437
| +17% | +$26.5K | ﹤0.01% | 2487 |
|
|
2021
Q1 | $168K | Buy |
2,510
+216
| +9% | +$16.9K | ﹤0.01% | 2392 |
|
|
2020
Q4 | $139K | Buy |
2,294
+443
| +24% | +$30.2K | ﹤0.01% | 2339 |
|
|
2020
Q3 | $146K | Sell |
1,851
-104
| -5% | -$8.29K | ﹤0.01% | 2239 |
|
|
2020
Q2 | $123K | Buy |
1,955
+1,251
| +178% | +$72.8K | ﹤0.01% | 2234 |
|
|
2020
Q1 | $37K | Hold |
704
| – | – | ﹤0.01% | 2165 |
|
|
2019
Q4 | $85K | Sell |
704
-54
| -7% | -$7.76K | ﹤0.01% | 2194 |
|
|
2019
Q3 | $138K | Sell |
758
-440
| -37% | -$62K | ﹤0.01% | 2165 |
|
|
2019
Q2 | $155K | Buy |
1,198
+103
| +9% | +$18.5K | ﹤0.01% | 2161 |
|
|
2019
Q1 | $267K | Sell |
1,095
-87
| -7% | -$23K | ﹤0.01% | 2068 |
|
|
2018
Q4 | $226K | Sell |
1,182
-155
| -12% | -$37.8K | ﹤0.01% | 2101 |
|
|
2018
Q3 | $439K | Buy |
1,337
+320
| +31% | +$98K | ﹤0.01% | 1985 |
|
|
2018
Q2 | $317K | Sell |
1,017
-167
| -14% | -$51K | ﹤0.01% | 2070 |
|
|
2018
Q1 | $288K | Buy |
1,184
+542
| +84% | +$152K | ﹤0.01% | 2033 |
|
|
2017
Q4 | $194K | Buy |
642
+274
| +74% | +$76.3K | ﹤0.01% | 2141 |
|
|
2017
Q3 | $97K | Sell |
368
-66
| -15% | -$19.1K | ﹤0.01% | 2144 |
|
|
2017
Q2 | $114K | Buy |
434
+16
| +4% | +$4.01K | ﹤0.01% | 2173 |
|
|
2017
Q1 | $150K | Hold |
418
| – | – | ﹤0.01% | 2114 |
|
|
2016
Q4 | $121K | Buy |
418
+11
| +3% | +$3.41K | ﹤0.01% | 2139 |
|
|
2016
Q3 | $138K | Buy |
407
+6
| +1% | +$2.19K | ﹤0.01% | 2079 |
|
|
2016
Q2 | $171K | Buy |
401
+16
| +4% | +$6.59K | ﹤0.01% | 2046 |
|
|
2016
Q1 | $123K | Sell |
385
-54
| -12% | -$18.4K | ﹤0.01% | 2066 |
|
|
2015
Q4 | $227K | Buy |
439
+9
| +2% | +$3.32K | ﹤0.01% | 2023 |
|
|
2015
Q3 | $126K | Buy |
430
+47
| +12% | +$16.7K | ﹤0.01% | 2083 |
|
|
2015
Q2 | $151K | Sell |
383
-318
| -45% | -$112K | ﹤0.01% | 2083 |
|
|
2015
Q1 | $212K | Buy |
701
+84
| +14% | +$20.5K | ﹤0.01% | 2015 |
|
|
2014
Q4 | $137K | Buy |
+617
| New | +$127K | ﹤0.01% | 2084 |
|
|
2014
Q2 | – | Sell |
-884
| Closed | -$279K | – | 2308 |
|
|
2014
Q1 | $279K | Buy |
+884
| New | +$281K | ﹤0.01% | 2014 |
|
Other funds holding TXMD
RCMNY
E
GF
Principal Financial Group's TXMD Position: Q2 2022 in Review
Principal Financial Group sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 2,466 shares — an estimated $47K sold.
Principal Financial Group first reported a position in TXMD in Q1 2014 and held it in 31 quarters. The position peaked at $439K in Q3 2018. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.
- Principal Financial Group reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
- Principal Financial Group sold 2,466 TherapeuticsMD shares in Q2 2022, an estimated $47K.
- Principal Financial Group first reported a position in TherapeuticsMD in Q1 2014 and held it in 31 quarters.
- Principal Financial Group's TherapeuticsMD position peaked at $439K in Q3 2018.
- 53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.
Based on Principal Financial Group's 13F filing for Q2 2022, filed 10 Aug 2022.